SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administration (FDA). The IND was submitted by the University of Rochester Medical Center, New York State, following the positive pre-clinical results reported in August 2021 at the Americas Hepato-Pancreato-Biliary Association conference in Miami, USA. The trial design approved by the FDA calls for PXS-5505 to be added to current chemotherapy standard of care; combination of a PD-L1 inhibitor and an anti-VEGF drug as first line therapy in newly diagnosed patients with unresectable HCC carcinoma.
Primary liver malignancies have doubled in incidence over the last two decades. These malignancies are now the 4th leading cause of cancer-related mortality worldwide with a 19.6% 5-year relative survival rates. Currently, just 20-30% HCC are resectable at presentation with many patients relying on chemotherapy. A prominent feature of HCC is the presence of highly fibrotic tissue that increases tumour stiffness, and decreases access of drugs into the tumour. Under the guidance of Dr. Roberto Hernandez-Alejandro, MD (Chief Division of Transplantation / Hepatobiliary Surgery), the research team at the University of Rochester Medical Center, New York State, have been investigating the role of lysyl oxidase enzymes in liver cancer and whether Pharmaxis' cancer drug PXS-5505 can improve the efficacy of current chemotherapy drugs by inhibiting these enzymes.
Dr. Roberto Hernandez-Alejandro said, "At the University of Rochester Wilmot Cancer Center, we are excited about the prospect of combining PXS-5505 with standard first line therapy for our unresectable hepatocellular carcinoma patients. The incidence of hepatocellular carcinoma is rising in part due to increasing incidence of cirrhosis and non-alcoholic steatohepatitis. Beyond resection, effective systemic therapies for this disease are lacking, thus new treatment regimens are of significant clinical need."
Dr. Nabeel Badri, (Wilmot Cancer Institute, University of Rochester) added, "PXS-5505 is a potent inhibitor of lysyl oxidase, a key enzyme in collagen crosslinking. By inhibiting the formation of fibrotic tissue in the tumor we hope to improve delivery and effectiveness of immunotherapy drugs which have so far had a limited impact of the survival of our patients. Through preclinical testing and translational research, we have developed a promising clinical trial design that has the potential to benefit these patients and improve our understanding of hepatocellular carcinoma."
The IND submitted by Rochester referenced the previous successful IND lodged by Pharmaxis for the ongoing phase 2 trial of PXS-5505 in myelofibrosis. The approved trial design envisages a dose escalation stage where the safety of PXS-5505 in combination with a PD-L1 inhibitor and an anti-VEGF drug will be assessed at several different doses as well as measures designed to explore the impact of PXS-5505 on fibrosis and drug perfusion. This will be followed by a 6-month trial of the selected dose with both safety and efficacy endpoints.
Pharmaxis CEO Gary Phillips said, "We highly value our collaboration with the research team at University of Rochester. The rapid progression from the compelling pre-clinical work presented for the first time in August to a successful IND submission is very encouraging and we look forward to concluding arrangements for the commencement of the dose escalation study in 2022. PXS-5505 has recently progressed to a phase 2 clinical trial looking for evidence of disease modifying effects in the bone cancer myelofibrosis as a monotherapy so exploring its additional potential to address cancers where fibrosis is limiting the clinical benefit of current chemotherapy- such as liver and pancreatic cancer- would be significantly value adding."
AUTHORISED FOR RELEASE TO ASX BY:
Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E [emailprotected]
CONTACT:
Media: Felicity Moffatt: T +61 418 677 701, E [emailprotected]Investor relations:Rudi Michelson (Monsoon Communications) T +61 411 402 737, E [emailprotected]
Join the Pharmaxis mailing listhere
Follow us: LinkedIn/Twitter
About Pharmaxis
Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.
Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021. PXS5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer.
Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy.
Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.
Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. http://www.pharmaxis.com.au
About PXS-5505
PXS-5505 is an orally taken drug that inhibits the lysyl oxidase family of enzymes, two members LOX and LOXL2 are strongly upregulated in human myelofibrosis. In pre-clinical models of myelofibrosis PXS-5505 reversed the bone marrow fibrosis that drives morbidity and mortality in myelofibrosis and reduced many of the abnormalities associated with this disease. It has already received IND approval and Orphan Drug Designation from the FDA.
Forward-looking statements
Forwardlooking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.
SOURCE Pharmaxis Limited
Originally posted here:
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer - PRNewswire
- No Rest For the Wicked | Review In Progress - XboxEra - April 27th, 2024 [April 27th, 2024]
- Maine made progress in wages and productivity, but still faces shrinking labor force - Press Herald - April 27th, 2024 [April 27th, 2024]
- The Progress Report: How 4 Schools Are Teaching Kids to Read and Seeing Success - Voice of San Diego - April 27th, 2024 [April 27th, 2024]
- PROGRESS MADE IN COLE REHAB? - Bleeding Yankee Blue - April 27th, 2024 [April 27th, 2024]
- Pollution or Progress? What's Next for LNG Development in the Rio Grande Valley - Progress Texas - April 27th, 2024 [April 27th, 2024]
- Lykos Therapeutics Makes Progress in Europe - The Dales Report - April 27th, 2024 [April 27th, 2024]
- Adelaide Film Fest Picks Five Works in Progress for Cannes Showcase, With Giant, Drafthouses Mockbuster Making the Cut (EXCLUSIVE) - Variety - April 27th, 2024 [April 27th, 2024]
- Washington says real progress needed before restoring UNRWA funding - The Times of Israel - April 27th, 2024 [April 27th, 2024]
- LIGA Provides Further Guidance: Engages Audit Firm and Making Progress in Search for CEO and Management Team - Yahoo Finance - April 27th, 2024 [April 27th, 2024]
- Forest Health Council Reports Progress Toward Community Wildfire Resiliency-Greg Felt Talks Wildfire Mitigation with ... - Heart of the Rockies Radio - April 27th, 2024 [April 27th, 2024]
- Football notes: Robert Livingston pleased with progress of CU Buffs defense - BuffZone - April 27th, 2024 [April 27th, 2024]
- Spencer Hospital Emergency Department Project Continuing to Progress - KICD - April 27th, 2024 [April 27th, 2024]
- Proof-of-Concept Exploit Released for Progress Software OpenEdge Vulnerability - The Hacker News - March 16th, 2024 [March 16th, 2024]
- Progress being made on fire alarms, Oswego town supervisor says - oswegocountynewsnow.com - March 16th, 2024 [March 16th, 2024]
- Progress on the Boyertown Express featured at Dinner - Berks Weekly - March 16th, 2024 [March 16th, 2024]
- Fire Crews Stop Forward Progress of Two-Acre Brush Fire Near Vandenberg - Santa Barbara Edhat - March 16th, 2024 [March 16th, 2024]
- Hopewell plans to install speed cameras at three city schools - Progress Index - March 16th, 2024 [March 16th, 2024]
- New numbers on progress of penny sales tax - The Post and Courier - March 16th, 2024 [March 16th, 2024]
- Long Island woman who survived acid attack continues to make progress in recovery - PIX11 New York News - March 16th, 2024 [March 16th, 2024]
- Beam marks progress toward bringing 1st-ever MLS team to San Diego - NBC San Diego - March 16th, 2024 [March 16th, 2024]
- McKone: Irish-American progress and paradoxes | Perspective | timesargus.com - Barre Montpelier Times Argus - March 16th, 2024 [March 16th, 2024]
- Big East reportedly making a lot of progress on media rights deals with CBS, Fox - Awful Announcing - March 16th, 2024 [March 16th, 2024]
- Berrien County farmers note slow progress on the new Farm Bill - News/Talk/Sports 94.9 WSJM - March 16th, 2024 [March 16th, 2024]
- END OF SESSION: Sen. Crider and Rep. Cherry reflect on progress made during the legislative session - Greenfield Daily Reporter - March 16th, 2024 [March 16th, 2024]
- Vowles being patient with Sargeant but expects to see "progress" - RaceFans - March 16th, 2024 [March 16th, 2024]
- Inflation ticked up in February, reversing some prior progress - ABC News - March 16th, 2024 [March 16th, 2024]
- Latest NEOM progress video of The Line is indicator of scale - Supercar Blondie - March 16th, 2024 [March 16th, 2024]
- Statewide Impact of Ohio Intel ProjectEvident in Initial Progress Report - Scioto Post - March 16th, 2024 [March 16th, 2024]
- SpaceX makes significant progress with third Starship orbital test flight - TechCrunch - March 16th, 2024 [March 16th, 2024]
- UPDATE: Forward progress stopped on vegetation fire near Lompoc - KSBY News - March 16th, 2024 [March 16th, 2024]
- Lady Rattlers and Diamondbacks ready to roll - Progresstimes - March 16th, 2024 [March 16th, 2024]
- SpaceX celebrates major progress on the third flight of Starship - Ars Technica - March 16th, 2024 [March 16th, 2024]
- Helldivers 2 Galactic War live map: Track status and progress with this Liberty-approved web app - Windows Central - March 16th, 2024 [March 16th, 2024]
- Pittsburgh police will only respond to calls of in-progress emergencies as part of new staffing plan - Police News - March 16th, 2024 [March 16th, 2024]
- A year of achievement, rebuilding and progress for utilities - Yoursun.com - March 16th, 2024 [March 16th, 2024]
- Trkiye: No Direct Dialogue with Damascus, No Progress in Normalization - Asharq Al-awsat - English - March 16th, 2024 [March 16th, 2024]
- A WORK IN PROGRESS | News | shelbynews.com - Shelbynews - March 16th, 2024 [March 16th, 2024]
- From recurrent networks to GPT-4: Measuring algorithmic progress in language models - Tech Xplore - March 16th, 2024 [March 16th, 2024]
- U.S. Inability To Address Nuclear Waste Harms Environmental Progress - Newsweek - March 16th, 2024 [March 16th, 2024]
- Park Progress - Greater Wilmington Business Journal - March 16th, 2024 [March 16th, 2024]
- SF supervisor to hold hearing on homeless-shelter progress | Housing | sfexaminer.com - San Francisco Examiner - March 16th, 2024 [March 16th, 2024]
- 'It's good to see progress being made on the site': Revised vision for Liberty Theater property in Libertyville - Daily Herald - March 16th, 2024 [March 16th, 2024]
- Diversity Among Emmy Winners Is a Result of Industry Progress - TheWrap - January 18th, 2024 [January 18th, 2024]
- What would Dr. King say about progress and 2024? - The Chicago Cusader - January 18th, 2024 [January 18th, 2024]
- Police: Petersburg woman reportedly used hammer to hit her boyfriend - Progress Index - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - AOL - January 18th, 2024 [January 18th, 2024]
- Lady Tigers Split Last Weeks Game's Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Lexington Police Investigate Shooting at Walmart Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Scotts Hill Lions Dominated Last Week Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Older Couple Rescued From Submerged Vehicle Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Fore-ward Progress | Bintelli's new River Ridge facility to focus on making electric golf carts - WDRB - January 18th, 2024 [January 18th, 2024]
- VIDEO: Project manager gives update on Glenn McConnell Widening progress - Live 5 News WCSC - January 18th, 2024 [January 18th, 2024]
- Truck driver sentenced for trafficking cocaine to Prince George County - Progress Index - January 18th, 2024 [January 18th, 2024]
- After decades of little progress, Milwaukee begins new approach to improve lives of Black men and boys - madison365.com - January 18th, 2024 [January 18th, 2024]
- Women are bored of waiting: Slow progress on shattering the glass ceiling on company boards - I by IMD - I by IMD - January 18th, 2024 [January 18th, 2024]
- Now Accepting Applications for the 2024 Progress Software Mary Szkely Scholarship for Women in STEM - GlobeNewswire - January 18th, 2024 [January 18th, 2024]
- "Some progress made" at Onslow BOE meeting, according to number of parents - WCTI12.com - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - Nonstop Local - January 18th, 2024 [January 18th, 2024]
- DeSantis took credit for Florida's progress but Iowa may have sniffed out his bravado | Opinion - Yahoo News Canada - January 18th, 2024 [January 18th, 2024]
- Has the Israeli Military Made Progress in Its Goal of Destroying Hamas? : State of the World from NPR - NPR - January 18th, 2024 [January 18th, 2024]
- Jan. 19 Panel Examines 30-Year Progress of Women in Research - Mirage News - January 18th, 2024 [January 18th, 2024]
- Ducks' Midseason Check-in: Progress, Improvement Areas & More - The Hockey Writers - January 18th, 2024 [January 18th, 2024]
- Companies are hiding their climate progress. A new report explains why. - Grist - January 18th, 2024 [January 18th, 2024]
- Lou Leonatti With Progress Mexico Gives Hospital Bankruptcy Hearing Update On AM 1340 KXEO Am I Awake Morning Show - KXEO - January 18th, 2024 [January 18th, 2024]
- Seaside Heights Wants to See Progress From Developers, Will Investigate 'Bamboo' Property - Shorebeat - January 18th, 2024 [January 18th, 2024]
- Progress over perfection: Is Coach modelling a path for fashion transformation? - Vogue Business - January 18th, 2024 [January 18th, 2024]
- Watch the video of the Edmonds armed robbery in progress - MyNorthwest - January 18th, 2024 [January 18th, 2024]
- Albemarle County house burns to the ground in late night fire - The Daily Progress - January 18th, 2024 [January 18th, 2024]
- GHDDI and Microsoft Research use AI technology to achieve significant progress in discovering new drugs to treat ... - Microsoft - January 18th, 2024 [January 18th, 2024]
- Henderson County Suspects Apprehended in Trenton Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- HCFD Reports Lowest Number of Residential Fires - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Unlocking The Future: CAGA's Progress In Web3 And Blockchain Innovation - Benzinga - January 18th, 2024 [January 18th, 2024]
- Underwhelming performance: Quarterbacks still a work in progress - Daily O'Collegian - September 3rd, 2023 [September 3rd, 2023]
- Governor Hochul Announces Progress in Increasing MTA Accessibility - ny.gov - September 3rd, 2023 [September 3rd, 2023]
- A progress report: The columnist's garden in September - Kennebec Journal and Morning Sentinel - September 3rd, 2023 [September 3rd, 2023]
- September 2023: Innovative researchers celebrate scientific ... - Environmental Factor Newsletter - September 3rd, 2023 [September 3rd, 2023]
- Progress over perfectionism - Lynn University - September 3rd, 2023 [September 3rd, 2023]
- Signs of progress on new Folsom Medical Office Building - UC Davis Health - September 3rd, 2023 [September 3rd, 2023]
- LA District FUDS team makes progress on Nellis Remedial Action ... - spl.usace.army.mil - September 3rd, 2023 [September 3rd, 2023]
- UFC Fight Night 226 winner Volkan Oezdemir pleased with progress after training with Khamzat Chimaev - Yahoo Sports - September 3rd, 2023 [September 3rd, 2023]